A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

被引：0
|
作者：
Ye, Ding-Wei
Gu, Weijie
Han, Weiqing
Luo, Hong
Zhou, Fangjian
He, Dalin
Ma, Lulin
Guo, Hongqian
Liang, Chaozhao
Chong, Tie
Jiang, Jun
Chen, Zhiwen
Wang, Yong
Zou, Qing
Tian, Ye
Xiao, Jun
Huang, Jian
Yang, Xinfeng
Li, Junliang
Jin, Chunlei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Ctr, Changsha, Peoples R China
[3] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Chongqing, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[6] Peking Univ Third Hosp, Beijing, Peoples R China
[7] Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[8] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China
[9] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
[10] Army Med Univ, Daping Hosp, Chongqing, Peoples R China
[11] Army Med Univ, Southwest Hosp, Chongqing, Peoples R China
[12] Tianjin Med Univ, Hosp 2, Tianjin, Peoples R China
[13] Jiangsu Canc Hosp, Nanjing, Peoples R China
[14] Capital Med Univ, Beijing Friendly Hosp, Beijing, Peoples R China
[15] USTC, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
[16] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[17] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[18] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5003
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)
    Tombal, B.
    Saad, F.
    Hussain, M.
    Sternberg, C. N.
    Fizazi, K.
    Crawford, E. D.
    Yamada, K.
    Kappeler, C.
    Kuss, I.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)
    Chi, K. N.
    Chowdhury, S.
    Radziszewski, P.
    Lebret, T.
    Ozguroglu, M.
    Sternberg, C.
    Sims, R. B.
    Yu, M.
    Naini, V.
    Darif, M.
    Merseburger, A. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
    Smith, Matthew Raymond
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alexeev, Boris
    Montesa, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe Melo
    Tammela, Teuvo
    Suzuki, Hiroyoshi
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
    Gratzke, Christian
    Niu Cuizhen
    Poehlein, Christian Heinrich
    Burgents, Joseph E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [35] Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial.
    Vaishampayan, Ulka N.
    Heilbrun, Lance K.
    Monk, Paul
    Tejwani, Sheela
    Sonpavde, Guru
    Smith, Daryn
    Jasti, Pallavi
    Dobson, Kimberlee
    Heath, Elisabeth I.
    Cher, Michael L.
    Chinni, Sreenivasa
    Fontana, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [36] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
    Burgess, Earle F.
    Grigg, Claud M.
    Boselli, Danielle
    Symanowski, James T.
    Golshayan, Alireza
    Graham, David L.
    Osei-Boateng, Kwabena
    Gavini, Nagajyothi
    Zhu, Jiang
    Brown, Landon C.
    Norek, Sarah
    Begic, Xhevahire J.
    Raghavan, Derek
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [37] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
    Gill, David Michael
    Stenehjem, David D.
    Cheng, Heather H.
    Kessler, Elizabeth Riley
    Hahn, Andrew W.
    Gupta, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [39] Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC)
    Iguchi, Taro
    Pu, Yeong-Shiau
    Kimura, Go
    Byun, Seok-Soo
    Ha, Hong Koo
    Hong, Jun Hyuk
    Li, Jian-Ri
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 96 - 97
  • [40] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
    Shore, Neal D.
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345